🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

IVERIC bio Inc (ISEE)

NASDAQ
Currency in USD
Disclaimer
39.950
0.000(0.00%)
Closed
Trading near 52-week High
Fair Value
Day's Range
39.85039.990
52 wk Range
9.39039.990
Prev. Close
39.95
Open
39.86
Day's Range
39.85-39.99
52 wk Range
9.39-39.99
Volume
0
Average Vol. (3m)
5,050,687
1-Year Change
0%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
ISEE Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.
Show more

IVERIC bio Inc Company Profile

IVERIC bio, Inc. operates as a biopharmaceutical company that focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed a Phase 2/3 clinical trial; GATHER2 is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in a Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high-temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 which has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprise the miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and the miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). IVERIC bio, Inc. was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc.

Compare ISEE to Peers and Sector

Metrics to compare
ISEE
Peers
Sector
Relationship
P/E Ratio
0.0x0.0x0.0x
PEG Ratio
0.000.000.00
Price / Book
0.0x0.0x0.0x
Price / LTM Sales
0.0x0.0x0.0x
Upside (Analyst Target)
0.0%0.0%0.0%
Fair Value Upside
Unlock0.0%0.0%Unlock
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.